New studies are fueling debate about whether the booster shot targeting the BA.4 and BA.5 versions of omicron is superior to another shot of the original.
Regeneron will supply an additional 1.4 million antibody doses to the United States, while Eli Lilly will provide 388,000 additional doses of its antibodies.
